Lilly putting $400M into U.S. diabetes production, adding 100 jobs
To confront rising insulin prices this year, Eli Lilly introduced a generic version of its Humalog priced at half the cost. Now the company is investing $400M in its Indianapolis production site so it can make more diabetes treatments and prepare for pipeline products. Along with technology and data analytics upgrades, this investment it will result in 100 new jobs.
